Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma

Hematology/Oncology Clinics of North America

Volumn 23, Issue 4, 2009, Pages 791-827

  de Leval, Laurence ^a   Hasserjian, Robert Paul ^b  

^a CHU SART TILMAN   (Belgium)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Burkitt; Burkitt like; Diagnosis; Diffuse large B cell lymphoma; Genetics; High grade; Pathology; WHO 2008 classification

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD19 ANTIGEN; CD20 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 4; METHOTREXATE; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR PAX5; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER MORPHOLOGY; CANCER RELAPSE; CHROMOSOME TRANSLOCATION; CHRONIC INFLAMMATION; CLINICAL FEATURE; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMATOID GRANULOMATOSIS; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN LYMPHOMA; SOMATIC MUTATION; SURVIVAL TIME;

ADULT; ANTIGENS, CD20; ANTIGENS, CD5; BURKITT LYMPHOMA; CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; WORLD HEALTH ORGANIZATION;

EID: 67649444318     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.04.004     Document Type: Review

References (162)

1. Fernandez de Sevilla S., Romagosa V., Domingo-Claros A., et al. Diffuse large B-cell lymphoma: is morphologic subdivision useful in clinical management?. Eur J Haematol 60 (1998) 202-208
2. Diebold J., Anderson J.R., Armitage J.O., et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 43 1 (2002) 97-104
3. Cabanillas F., Velasquez W.S., Hagemeister F.B., et al. Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood 79 4 (1992) 1024-1028
4. Kremer M., Spitzer M., Mandl-Weber S., et al. Discordant bone marrow involvement in diffuse large B-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders. Lab Invest 83 1 (2003) 107-114
5. Davis T., Czerwinski K., and Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 5 (1999) 611-615
6. Yamaguchi M., Seto M., Okamoto M., et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99 (2002) 815-821
7. Ennishi D., Takeuchi K., Yokoyama M., et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 19 11 (2008) 1921-1926
8. Kuppers R., Klein U., Hansmann M.L., et al. Cellular origin of human B-cell lymphomas. N Engl J Med 341 20 (1999) 1520-1529
9. Bea S., Colomo L., Lopez-Guillermo A., et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 22 17 (2004) 3498-3506
10. Chaganti R.S., Nanjangud G., Schmidt H., et al. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. Semin Hematol 37 4 (2000) 396-411
11. Pasqualucci L., Neumeister P., Goossens T., et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412 6844 (2001) 341-346
12. Dent A., Vasanwala F., and Toney L. Regulation of gene expression by the proto-oncogene BCL-6. Crit Rev Oncol Hematol 41 (2002) 1-9
13. Phan R.T., and Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432 7017 (2004) 635-639
14. Bastard C., Deweindt C., Kerckaert J.P., et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 83 9 (1994) 2423-2427
15. Barrans S., O'Connor S., Evans P., et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 117 (2002) 322-332
16. Hermine O., Haioun C., Lepage E., et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87 1 (1996) 265-272
17. Gascoyne R.D., Adomat S.A., Krajewski S., et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90 1 (1997) 244-251
18. Pasqualucci L., Migliazza A., Basso K., et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 101 8 (2003) 2914-2923
19. Young K.H., Leroy K., Moller M.B., et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 112 8 (2008) 3088-3098
20. Houldsworth J., Olshen A.B., Cattoretti G., et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood 103 5 (2004) 1862-1868
21. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. [In Process Citation]. Nature 403 6769 (2000) 503-511
22. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 25 (2002) 1937-1947
23. Lenz G., Wright G.W., Emre N.C., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105 36 (2008) 13520-13525
24. Lossos I.S., Alizadeh A.A., Eisen M.B., et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A 97 18 (2000) 10209-10213
25. Iqbal J., Greiner T.C., Patel K., et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21 11 (2007) 2332-2343
26. Ngo V.N., Davis R.E., Lamy L., et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441 7089 (2006) 106-110
27. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359 22 (2008) 2313-2323
28. Lossos I.S., Czerwinski D.K., Alizadeh A.A., et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350 18 (2004) 1828-1837
29. Rimsza L.M., Leblanc M.L., Unger J.M., et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112 8 (2008) 3425-3433
30. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 1 (2004) 275-282
31. de Jong D., Rosenwald A., Chhanabhai M., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25 7 (2007) 805-812
32. Barrans S.L., Carter I., Owen R.G., et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99 4 (2002) 1136-1143
33. Chang C.C., McClintock S., Cleveland R.P., et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28 4 (2004) 464-470
34. Colomo L., Lopez-Guillermo A., Perales M., et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101 1 (2003) 78-84
35. De Paepe P., Achten R., Verhoef G., et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 23 28 (2005) 7060-7068
36. Nyman H., Adde M., Karjalainen-Lindsberg M.L., et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109 11 (2007) 4930-4935
37. de Leval L., and Harris N.L. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 43 6 (2003) 509-528
38. Lossos I.S., and Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24 6 (2006) 995-1007
39. Shipp M.A., Ross K.N., Tamayo P., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 1 (2002) 68-74
40. Banham A.H., Connors J.M., Brown P.J., et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11 3 (2005) 1065-1072
41. Natkunam Y., Farinha P., Hsi E.D., et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 26 3 (2008) 447-454
42. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 26 25 (2007) 3603-3613
43. Dogan A., Burke J.S., Goteri G., et al. Micronodular T-cell/histiocyte-rich large B-cell lymphoma of the spleen: histology, immunophenotype, and differential diagnosis. Am J Surg Pathol 27 7 (2003) 903-911
44. Lim M.S., Beaty M., Sorbara L., et al. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells. Am J Surg Pathol 26 11 (2002) 1458-1466
45. Achten R., Verhoef G., Vanuytsel L., et al. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology 40 1 (2002) 31-45
46. Rudiger T., Ott G., Ott M.M., et al. Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Am J Surg Pathol 22 10 (1998) 1184-1191
47. Nam-Cha S.H., Roncador G., Sanchez-Verde L., et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol 32 8 (2008) 1252-1257
48. Monti S., Savage K.J., Kutok J.L., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105 5 (2005) 1851-1861
49. Rudiger T., Gascoyne R.D., Jaffe E.S., et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 13 Suppl 1 (2002) 44-51
50. Franke S., Wlodarska I., Maes B., et al. Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol 161 5 (2002) 1861-1867
51. Maes B., Anastasopoulou A., Kluin-Nelemans J.C., et al. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features. Ann Oncol 12 6 (2001) 853-858
52. Bouabdallah R., Mounier N., Guettier C., et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol 21 7 (2003) 1271-1277
53. Batchelor T., and Loeffler J.S. Primary CNS lymphoma. J Clin Oncol 24 8 (2006) 1281-1288
54. Braaten K.M., Betensky R.A., de Leval L., et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 9 3 (2003) 1063-1069
55. Camilleri-Broet S., Criniere E., Broet P., et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107 1 (2006) 190-196
56. Montesinos-Rongen M., Siebert R., and Deckert M. Primary lymphoma of the central nervous system: just DLBCL or not?. Blood 113 1 (2009) 7-10
57. Cady F.M., O'Neill B.P., Law M.E., et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 26 29 (2008) 4814-4819
58. Rubenstein J.L., Fridlyand J., Shen A., et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 107 9 (2006) 3716-3723
59. Montesinos-Rongen M., Brunn A., Bentink S., et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 22 2 (2008) 400-405
60. Tun H.W., Personett D., Baskerville K.A., et al. Pathway analysis of primary central nervous system lymphoma. Blood 111 6 (2008) 3200-3210
61. Dijkman R., Tensen C.P., Buettner M., et al. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood 107 12 (2006) 4926-4929
62. Hoefnagel J.J., Dijkman R., Basso K., et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105 9 (2005) 3671-3678
63. Oyama T., Ichimura K., Suzuki R., et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27 1 (2003) 16-26
64. Oyama T., Yamamoto K., Asano N., et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 13 17 (2007) 5124-5132
65. Shimoyama Y., Oyama T., Asano N., et al. Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review. J Clin Exp Hematop 46 1 (2006) 1-4
66. Park S., Lee J., Ko Y.H., et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110 3 (2007) 972-978
67. Addis B.J., and Isaacson P.G. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology 10 4 (1986) 379-390
68. Isaacson P., Norton A., and Addis B. The human thymus contains a novel population of B-lymphocytes. Lancet ii (1987) 1488-1490
69. Jacobson J., Aisenberg A., Lamarre L., et al. Mediastinal large cell lymphoma: an uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 62 (1988) 1893-1898
70. Cazals-Hatem D., Lepage E., Brice P., et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol 20 7 (1996) 877-888
71. Zinzani P.L., Martelli M., Bendandi M., et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 86 2 (2001) 187-191
72. Rosenwald A., Wright G., Leroy K., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198 6 (2003) 851-862
73. Lamarre L., Jacobson J.O., Aisenberg A.C., et al. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol 13 9 (1989) 730-739
74. Pileri S.A., Gaidano G., Zinzani P.L., et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 162 1 (2003) 243-253
75. de Leval L., Ferry J.A., Falini B., et al. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells?. Am J Surg Pathol 25 10 (2001) 1277-1282
76. Calaminici M., Piper K., Lee A.M., et al. CD23 expression in mediastinal large B-cell lymphomas. Histopathology 45 6 (2004) 619-624
77. Copie-Bergman C., Plonquet A., Alonso M.A., et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 15 11 (2002) 1172-1180
78. Copie-Bergman C., Boulland M.L., Dehoulle C., et al. Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood 101 7 (2003) 2756-2761
79. Savage K.J., Monti S., Kutok J.L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin's lymphoma. Blood 102 12 (2003) 3871-3879
80. Rodig S.J., Savage K.J., LaCasce A.S., et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 31 1 (2007) 106-112
81. Leithauser F., Bauerle M., Huynh M.Q., et al. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 98 9 (2001) 2762-2770
82. Tsang P., Cesarman E., Chadburn A., et al. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol 148 6 (1996) 2017-2025
83. Joos S., Otano-Joos M.I., Ziegler S., et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87 4 (1996) 1571-1578
84. Wessendorf S., Barth T.F., Viardot A., et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 21 12 (2007) 2463-2469
85. Joos S., Granzow M., Holtgreve-Grez H., et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 103 4 (2003) 489-495
86. Feuerhake F., Kutok J.L., Monti S., et al. NF{kappa}B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106 4 (2005) 1392-1399
87. Guiter C., Dusanter-Fourt I., Copie-Bergman C., et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 104 2 (2004) 543-549
88. Melzner I., Bucur A.J., Bruderlein S., et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105 6 (2005) 2535-2542
89. Weniger M.A., Melzner I., Menz C.K., et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25 18 (2006) 2679-2684
90. Renne C., Willenbrock K., Martin-Subero J.I., et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 21 4 (2007) 780-787
91. Rudiger T., Jaffe E.S., Delsol G., et al. Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Ann Oncol 9 Suppl 5 (1998) S31-S38
92. Traverse-Glehen A., Pittaluga S., Gaulard P., et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29 11 (2005) 1411-1421
93. Calvo K.R., Traverse-Glehen A., Pittaluga S., et al. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol 11 5 (2004) 227-238
94. Murase T., Nakamura S., Kawauchi K., et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 111 3 (2000) 826-834
95. Ferreri A.J., Dognini G.P., Bairey O., et al. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. Br J Haematol 143 2 (2008) 253-257
96. Khalidi H.S., Brynes R.K., Browne P., et al. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Mod Pathol 11 10 (1998) 983-988
97. Ponzoni M., Ferreri A.J., Campo E., et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 25 21 (2007) 3168-3173
98. Ferreri A.J., Campo E., Seymour J.F., et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 127 2 (2004) 173-183
99. Yegappan S., Coupland R., Arber D.A., et al. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma. Mod Pathol 14 11 (2001) 1147-1156
100. Ponzoni M., Arrigoni G., Gould V.E., et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 31 2 (2000) 220-226
101. Nakatsuka S., Yao M., Hoshida Y., et al. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 20 20 (2002) 4255-4260
102. Petitjean B., Jardin F., Joly B., et al. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B-and T-cell phenotype. Am J Surg Pathol 26 6 (2002) 724-732
103. Kanno H., and Aozasa K. Mechanism for the development of pyothorax-associated lymphoma. Pathol Int 48 9 (1998) 653-664
104. Yamato H., Ohshima K., Suzumiya J., et al. Evidence for local immunosuppression and demonstration of c-myc amplification in pyothorax-associated lymphoma. Histopathology 39 2 (2001) 163-171
105. Nishiu M., Tomita Y., Nakatsuka S., et al. Distinct pattern of gene expression in pyothorax-associated lymphoma (PAL), a lymphoma developing in long-standing inflammation. Cancer Sci 95 10 (2004) 828-834
106. Takakuwa T., Tresnasari K., Rahadiani N., et al. Cell origin of pyothorax-associated lymphoma: a lymphoma strongly associated with Epstein-Barr virus infection. Leukemia 22 3 (2008) 620-627
107. Copie-Bergman C., Niedobitek G., Mangham D.C., et al. Epstein-Barr virus in B-cell lymphomas associated with chronic suppurative inflammation. J Pathol 183 3 (1997) 287-292
108. Cheuk W., Chan A.C., Chan J.K., et al. Metallic implant-associated lymphoma: a distinct subgroup of large B-cell lymphoma related to pyothorax-associated lymphoma?. Am J Surg Pathol 29 6 (2005) 832-836
109. Guinee Jr. D., Jaffe E., Kingma D., et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 18 8 (1994) 753-764
110. Beaty M.W., Toro J., Sorbara L., et al. Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features. Am J Surg Pathol 25 9 (2001) 1111-1120
111. Saxena A., Dyker K.M., Angel S., et al. Posttransplant diffuse large B-cell lymphoma of "lymphomatoid granulomatosis" type. Virchows Arch 441 6 (2002) 622-628
112. Myers J.L., Kurtin P.J., Katzenstein A.L., et al. Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol 19 11 (1995) 1300-1312
113. Delecluse H.J., Anagnostopoulos I., Dallenbach F., et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89 4 (1997) 1413-1420
114. Colomo L., Loong F., Rives S., et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 28 6 (2004) 736-747
115. Teruya-Feldstein J., Chiao E., Filippa D.A., et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogeneous spectrum in both HIV-positive and -negative patients. Ann Oncol 15 11 (2004) 1673-1679
116. Dong H.Y., Scadden D.T., de Leval L., et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr Virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol 29 12 (2005) 1633-1641
117. Chadburn A., Hyjek E., Mathew S., et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 28 11 (2004) 1401-1416
118. Vega F., Chang C.C., Medeiros L.J., et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18 6 (2005) 806-815
119. Delsol G., Lamant L., Mariame B., et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 89 5 (1997) 1483-1490
120. Gascoyne R.D., Lamant L., Martin-Subero J.I., et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 102 7 (2003) 2568-2573
121. Onciu M., Behm F.G., Downing J.R., et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 102 7 (2003) 2642-2644
122. Cesarman E., Chang Y., Moore P.S., et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332 18 (1995) 1186-1191
123. Horenstein M.G., Nador R.G., Chadburn A., et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 90 3 (1997) 1186-1191
124. Gaidano G., Gloghini A., Gattei V., et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood 90 12 (1997) 4894-4900
125. Jenner R.G., Maillard K., Cattini N., et al. Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 100 18 (2003) 10399-10404
126. Klein U., Gloghini A., Gaidano G., et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101 10 (2003) 4115-4121
127. Boulanger E., Gerard L., Gabarre J., et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23 19 (2005) 4372-4380
128. Oksenhendler E., Boulanger E., Galicier L., et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99 7 (2002) 2331-2336
129. Dupin N., Diss T.L., Kellam P., et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95 4 (2000) 1406-1412
130. Raphael M., Gentilhomme O., Tulliez M., et al. Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. Arch Pathol Lab Med 115 1 (1991) 15-20
131. Burmeister T., Schwartz S., Horst H.A., et al. Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia 19 8 (2005) 1391-1398
132. Hecht J.L., and Aster J.C. Molecular biology of Burkitt's lymphoma. J Clin Oncol 18 21 (2000) 3707-3721
133. Magrath I.T., Janus C., Edwards B.K., et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63 5 (1984) 1102-1111
134. Hummel M., Bentink S., Berger H., et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354 23 (2006) 2419-2430
135. Dogan A., Bagdi E., Munson P., et al. CD10 and bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 24 (2000) 846-852
136. Rodig S.J., Vergilio J.A., Shahsafaei A., et al. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol 32 1 (2008) 113-122
137. Chuang S.S., Ye H., Du M.Q., et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Pathol 128 4 (2007) 558-564
138. Lim S.T., Karim R., Tulpule A., et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 23 33 (2005) 8477-8482
139. Rochford R., Cannon M.J., and Moormann A.M. Endemic Burkitt's lymphoma: a polymicrobial disease?. Nat Rev Microbiol 3 2 (2005) 182-187
140. Robbiani D.F., Bothmer A., Callen E., et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 135 6 (2008) 1028-1038
141. Bellan C., Lazzi S., Hummel M., et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 106 3 (2005) 1031-1036
142. Shiramizu B., Barriga F., Neequaye J., et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 77 7 (1991) 1516-1526
143. Boerma E.G., Siebert R., Kluin P.M., et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. Leukemia 23 2 (2009) 225-234
144. Gaidano G., and Dalla-Favera R. Molecular pathogenesis of AIDS-related lymphomas. Adv Cancer Res 67 (1995) 113-153
145. Leucci E., Cocco M., Onnis A., et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 216 4 (2008) 440-450
146. Dave S.S., Fu K., Wright G.W., et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354 23 (2006) 2431-2442
147. Blum K.A., Lozanski G., and Byrd J.C. Adult Burkitt leukemia and lymphoma. Blood 104 10 (2004) 3009-3020
148. Nomura Y., Karube K., Suzuki R., et al. High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients. Cancer Sci 99 2 (2008) 246-252
149. Magrath I., Adde M., Shad A., et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14 3 (1996) 925-934
150. Mead G.M., Sydes M.R., Walewski J., et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13 8 (2002) 1264-1274
151. Divine M., Casassus P., Koscielny S., et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 16 12 (2005) 1928-1935
152. Cairo M.S., Sposto R., Perkins S.L., et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol 120 4 (2003) 660-670
153. Soussain C., Patte C., Ostronoff M., et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85 3 (1995) 664-674
154. Patte C., Auperin A., Gerrard M., et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109 7 (2007) 2773-2780
155. Haralambieva E., Boerma E.J., van Imhoff G.W., et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 29 8 (2005) 1086-1094
156. McClure R.F., Remstein E.D., Macon W.R., et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 29 12 (2005) 1652-1660
157. Le Gouill S., Talmant P., Touzeau C., et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 92 10 (2007) 1335-1342
158. Kanungo A., Medeiros L.J., Abruzzo L.V., et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 19 1 (2006) 25-33
159. van Imhoff G.W., Boerma E.J., van der Holt B., et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24 25 (2006) 4135-4142
160. Leoncini L., Delsol G., Gascoyne R.D., et al. Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. Histopathology 46 3 (2005) 241-255
161. Knezevich S., Ludkovski O., Salski C., et al. Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia 19 4 (2005) 659-663
162. Macpherson N., Lesack D., Klasa R., et al. Small noncleaved, non-Burkitt's (Burkitt-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 17 5 (1999) 1558-1567